Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL 33416, USA.
Ther Drug Monit. 2013 Aug;35(4):443-9. doi: 10.1097/FTD.0b013e31828b2a50.
To compare and contrast the pharmacokinetic/pharmacodynamic foundations of traditional "peak-trough" vancomycin dosing methods versus newer "area under the curve" (AUC) strategies. To propose a new AUC-based dosing chart for empirically determining an initial vancomycin dosing regimen designed to achieve a desired AUC24 using the minimum inhibitory concentration (MIC), creatinine clearance (CrCl), and vancomycin clearance (ClVanco).
Peak-trough vancomycin dosing is designed to achieve a Cpeak of 20-40 mg/L and a Ctrough of 10-15 or 15-20 mg/L, depending on the severity of the infection and the nature of the pathogen. New treatment guidelines for vancomycin suggest that therapy should achieve an AUC24/MIC of ≥400. AUC-based vancomycin dosing derives the daily dose from ClVanco, MIC, and the desired AUC24/MIC, without consideration of the patient's weight.
A vancomycin dosing chart is proposed that estimates ClVanco using the following formula developed by Matzke et al: ClVanco in L/h = [(CrClmL/min × 0.689) + 3.66] × 0.06, which simplifies to (CrClmL/min × 0.41) + 0.22. Two levels of dosing are included-high dose (Ctrough: 15-20 mg/L) and moderate dose (Ctrough: 10-15 mg/L). Although the chart has not been validated clinically, it represents the product of standard dosing equations that are used to determine a starting dosing regimen based on well-established vancomycin pharmacokinetic parameters.
An understanding of pharmacokinetic and pharmacodynamic principles, including the relevance of AUC in relation to MIC, enables clinicians to make the best use of vancomycin dosing options. The proposed dosing chart is pharmacokinetically valid but has yet to be applied clinically. It provides a foundation for further study of how clinicians can determine an optimal AUC-based starting vancomycin dosing regimen without having to derive ClVanco or AUC24.
比较和对比传统“峰谷”万古霉素给药方法与新的“曲线下面积”(AUC)策略的药代动力学/药效学基础。提出一种新的基于 AUC 的给药图表,用于根据最小抑菌浓度(MIC)、肌酐清除率(CrCl)和万古霉素清除率(ClVanco)经验确定初始万古霉素给药方案,以达到所需的 AUC24。
峰谷万古霉素给药旨在达到 Cpeak 为 20-40mg/L 和 Ctrough 为 10-15 或 15-20mg/L,具体取决于感染的严重程度和病原体的性质。万古霉素新治疗指南建议,治疗应达到 AUC24/MIC≥400。基于 AUC 的万古霉素给药从 ClVanco、MIC 和所需的 AUC24/MIC 中得出每日剂量,而不考虑患者的体重。
新的 AUC 给药图表:提出了一种万古霉素给药图表,该图表使用 Matzke 等人开发的以下公式估算 ClVanco:ClVanco 以 L/h 计 = [(CrClmL/min×0.689) + 3.66]×0.06,简化为 (CrClmL/min×0.41) + 0.22。该图表包括两种给药水平-高剂量(Ctrough:15-20mg/L)和中剂量(Ctrough:10-15mg/L)。虽然该图表尚未在临床上得到验证,但它代表了用于根据已确立的万古霉素药代动力学参数确定起始给药方案的标准给药方程的产物。
了解药代动力学和药效学原则,包括 AUC 与 MIC 的相关性,使临床医生能够充分利用万古霉素给药选择。所提出的给药图表在药代动力学上是有效的,但尚未在临床上应用。它为进一步研究临床医生如何确定基于 AUC 的最佳起始万古霉素给药方案提供了基础,而无需推导 ClVanco 或 AUC24。